Skip to content
Screener

Innoviva, Inc. INVA Shares (Diluted)

Shares (Diluted) at other companies

Pfizer logo
PfizerPFE
5.7B-0.1%
AbbVie logo
AbbVieABBV
1.8B0.0%
Insmed logo
InsmedINSM
217.4M+14.8%
Savara logo
SavaraSVRA
253.3M+17.2%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
45.1M+32.9%
Theravance Biopharma logo
Theravance BiopharmaTBPH
51.3M+3.2%

Other financials

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.53B+33.1%
Enterprise value$1.22B+2.1%
P/E4.3×-25.4×
P/S3.5×+0.4×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Income tax benefit (expense), net24,600(8,910)(23,368)(16,905)
Net income (loss) and comprehensive income (loss)$(83,420)$63,688$103,175$17,104
Net income (loss) per share:
Basic$(1.14)$1.01$1.40$0.27
Diluted$(1.14)$0.77$1.25$0.24
Shares used to compute net income (loss) per share:
Basic73,42162,86573,78962,787
Diluted73,42184,45284,52984,342

Item 1. Financial Statements

FAQ

What is Innoviva, Inc.'s shares (diluted)?
Innoviva, Inc. (INVA) reported shares (diluted) of 73.4M in Q2 2026.
How has Innoviva, Inc.'s shares (diluted) changed year-over-year?
Innoviva, Inc.'s shares (diluted) decreased by 13.1% year-over-year, from 84.5M to 73.4M.
What is the long-term trend for Innoviva, Inc.'s shares (diluted)?
Over 4 years (2021 to 2025), Innoviva, Inc.'s shares (diluted) has grown at a -5.1% compound annual growth rate (CAGR), from 390.3M to 316.9M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Innoviva, Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude